Real-time Estimate Quote. Real-time Estimate  - 10/18 03:59:55 pm
42.17EUR +1.49%

PRESS RELEASE: Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse

04/20/2021 | 01:32am
DGAP-News: Evotec SE / Key word(s): Miscellaneous 
Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse 
2021-04-20 / 07:30 
The issuer is solely responsible for the content of this announcement. 
Hamburg, Germany, 20 April 2021: 
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced that the Company has 
initiated the construction of its J.POD^(R) 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, 
France. J.POD^(R) 2 EU, Evotec's second innovative cGMP biomanufacturing facility, will employ Just - Evotec Biologics' 
cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations 
housed inside autonomous cleanrooms. 
J.POD^(R) 2 EU will be Evotec's first commercial biomanufacturing facility in Europe and is anticipated to deliver much 
needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of Evotec's 
first J.POD^(R) 1 US in Redmond, Washington is proceeding on schedule and will be fully operational in H2 2021. 
With its wholly owned subsidiary, Just - Evotec Biologics, Evotec is ideally positioned to build the capacity required 
for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. Evotec is 
supporting multiple projects against COVID-19, including partnerships with the Bill & Melinda Gates Foundation and the 
United States Department of Defense. 
In addition to J.POD^(R) technology, Evotec is building unparalleled data-driven scientific capabilities to meet future 
viral threats, which include fast discovery, optimisation and development of novel therapeutic agents. 
The build-up of J.POD^(R) 2 EU will be supported with up to EUR 50 m from the French government, the Occitanie Region, 
Bpifrance, the Haute-Garonne prefecture as well as Toulouse Métropole. The total investment hat Evotec plans to 
undertake is currently estimated at approx. EUR 150 m. 
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "The global availability and accessibility of highly 
effective biotherapeutics has been Just - Evotec Biologics' mission right from the start. The ongoing coronavirus 
pandemic has underlined the need for flexible and nearshore biomanufacturing capacities. We are very grateful that 
through the support of the French government as well as all local institutions, we can now continue to deliver on this 
mission with the construction of Europe's first J.POD^(R) facility, this is critical for society." 
Evotec's Toulouse site, the Campus Curie, was recently expanded through the acquisition of "Biopark by Sanofi." Evotec 
has been operating in France since 2015. Construction of the J.POD^(R) 2 EU facility is expected to begin in H2 2021, 
and is expected to be fully operational in 2023. 
Dr Craig Johnstone, Chief Operating Officer of Evotec, commented: "With Just - Evotec Biologics, Evotec has 
world-leading expertise for biologics discovery, process development and production. We are very pleased with the 
market response and demand for J.POD^(R) 1 US even ahead of completion, so this second J.POD^(R) facility is a 
significant expansion of our capacity of disruptive and transformational bioproduction. In addition, the flexibility of 
the modular J.POD^(R) setup also creates potential opportunities for cell and gene therapy biomanufacturing. These 
modalities, which are also an integral part of our data-driven R&D Autobahn to Cures, therefore also stand to benefit 
from this new facility. I would also like to thank our partners in France for their help and support in creating this 
J.POD^(R) 2 EU to broaden global access to important biologics therapies." 
Agnès Pannier-Runacher, French Minister for Industry: "The French Government invests in healthcare and other strategic 
sectors for our industrial sovereignty. This announcement from Evotec in the Occitanie Region exemplifies our 
determination to relocate production activities in France, in particular regarding biotherapies which are at the core 
of drug innovation these past years. We will continue to deploy our strategy in accelerating the Investing for Future 
Carole Delga, President of the Occitanie / Pyrenees-Mediterranee Region: "Evotec's decision to locate its new European 
production plant in the Occitanie region highlights the richness of the local innovative biotherapy sector, and in 
particular the excellent complementarity between all the players in the value chain, which ranges from cutting-edge 
research laboratories to university hospitals and bioproduction facilities. This project is fully in line with the 
ambitions of the Occitanie Region, which aims to respond to the current major issues of relocation and sovereignty, as 
emphasized by the health crisis, through supporting projects that strengthen the autonomy and resilience of strategic 
industrial sectors, including the health sector." 
Jean-Luc Moudenc, President of Toulouse Métropole, Mayor of Toulouse: "The opening of a manufacturing plant, the 
concrete expression of Evotec's development in Toulouse, since the creation of its main site in France in 2015 on the 
Health Campus of the Future - Oncopole, is excellent news that illustrates the vitality of our metropolis. In addition 
to the job creation that will accompany the creation of this new factory, Evotec will strengthen all of the companies 
present in our territory in the field of Biomedicines, a field with a high stake in the fight against the sanitarian 
crisis. Toulouse Metropole supports the relocation of production, which contributes to the national and European 
industrial sovereignty, and leads a voluntarist action in favor of the Medicine of the Future. Evotec is fully in line 
with this strategy." 
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative 
product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and 
venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and 
integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the 
industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has 
established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies 
as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and 
complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare 
diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned 
product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple 
long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo 
Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us 
on Twitter @Evotec. 
Information set forth in this press release contains forward-looking statements, which involve a number of risks and 
uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this 
press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of 
risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ 
materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or 
undertaking to release publicly any updates or revisions to any such statements to reflect any change in our 
expectations or any change in events, conditions or circumstances on which any such statement is based. 
Media Contact Evotec SE: 
Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, 
IR Contact Evotec SE: 
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com 
2021-04-20 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
Language:     English 
Company:      Evotec SE 
              Manfred Eigen Campus / Essener Bogen 7 
              22419 Hamburg 
Phone:        +49 (0)40 560 81-0 
Fax:          +49 (0)40 560 81-222 
E-mail:       info@evotec.com 
Internet:     www.evotec.com 
ISIN:         DE0005664809 
WKN:          566480 
Indices:      MDAX, TecDAX 
Listed:       Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1186420 
End of News   DGAP News Service 

(MORE TO FOLLOW) Dow Jones Newswires

April 20, 2021 01:31 ET (05:31 GMT)

Copier lien
All news about EVOTEC SE
7d ago
7d ago
7d ago
7d ago
7d ago